167.86
price down icon2.00%   -3.42
after-market  After Hours:  167.86 
loading
Repligen Corp. stock is currently priced at $167.86, with a 24-hour trading volume of 534.82K. It has seen a -2.00% decreased in the last 24 hours and a -15.24% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $170.3 pivot point. If it approaches the $166.4 support level, significant changes may occur.
Previous Close:
$171.28
Open:
$169.82
24h Volume:
534.82K
Market Cap:
$9.37B
Revenue:
$638.76M
Net Income/Loss:
$41.58M
P/E Ratio:
82.69
EPS:
2.03
Net Cash Flow:
$74.93M
1W Performance:
+4.27%
1M Performance:
-15.24%
6M Performance:
+20.09%
1Y Performance:
-0.20%
1D Range:
Value
$165.91
$173.48
52W Range:
Value
$110.45
$211.13

Repligen Corp. Stock (RGEN) Company Profile

Name
Name
Repligen Corp.
Name
Phone
781-250-0111
Name
Address
Building 1, Suite 100 41 Seyon Street, Waltham, MA
Name
Employee
476
Name
Twitter
@repligen
Name
Next Earnings Date
2024-05-01
Name
Latest SEC Filings
Name
RGEN's Discussions on Twitter

Repligen Corp. Stock (RGEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-04-23 Downgrade The Benchmark Company Buy → Hold
Jul-20-23 Initiated Wells Fargo Overweight
Jul-05-23 Resumed JP Morgan Overweight
Mar-28-23 Initiated The Benchmark Company Buy
Dec-14-22 Initiated Deutsche Bank Hold
Dec-07-22 Initiated RBC Capital Mkts Sector Perform
Jul-20-22 Initiated UBS Buy
Oct-14-21 Initiated Exane BNP Paribas Outperform
Nov-10-20 Initiated KeyBanc Capital Markets Overweight
Aug-24-20 Reiterated H.C. Wainwright Buy
Jun-30-20 Reiterated H.C. Wainwright Buy
May-07-20 Reiterated H.C. Wainwright Buy
Mar-23-20 Reiterated H.C. Wainwright Buy
Nov-15-19 Initiated Stifel Buy
Nov-01-19 Upgrade First Analysis Sec Outperform → Strong Buy
Oct-15-19 Initiated SVB Leerink Outperform
Aug-28-19 Reiterated First Analysis Sec Outperform
Aug-23-19 Resumed Stephens Overweight
Jul-22-19 Upgrade H.C. Wainwright Neutral → Buy
Dec-17-18 Upgrade CL King Neutral → Buy
Nov-12-18 Downgrade CL King Buy → Neutral
Sep-26-18 Initiated H.C. Wainwright Neutral
Dec-08-17 Initiated Citigroup Buy
Dec-05-17 Initiated JP Morgan Overweight
Nov-13-17 Initiated CL King Buy
Oct-02-17 Upgrade First Analysis Sec Equal-Weight → Overweight
Jul-21-17 Initiated William Blair Outperform
Feb-13-17 Upgrade Piper Jaffray Neutral → Overweight
View All

Repligen Corp. Stock (RGEN) Financials Data

Repligen Corp. (RGEN) Revenue 2024

RGEN reported a revenue (TTM) of $638.76 million for the quarter ending December 31, 2023, a -20.31% decline year-over-year.
loading

Repligen Corp. (RGEN) Net Income 2024

RGEN net income (TTM) was $41.58 million for the quarter ending December 31, 2023, a -77.64% decrease year-over-year.
loading

Repligen Corp. (RGEN) Cash Flow 2024

RGEN recorded a free cash flow (TTM) of $74.93 million for the quarter ending December 31, 2023, a +93.43% increase year-over-year.
loading

Repligen Corp. (RGEN) Earnings per Share 2024

RGEN earnings per share (TTM) was $0.72 for the quarter ending December 31, 2023, a -77.85% decline year-over-year.
loading

Repligen Corp. Stock (RGEN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
KURIYEL RALF
Senior VP, R&D
Mar 11 '24
Option Exercise
86.10
1,271
109,433
27,777
KURIYEL RALF
Senior VP, R&D
Mar 11 '24
Sale
193.73
3,517
681,348
24,260
Hunt Anthony
Chief Executive Officer
Mar 08 '24
Option Exercise
16.55
1
17
201,956
Hunt Anthony
Chief Executive Officer
Mar 08 '24
Sale
197.44
16,707
3,298,632
185,249
DAWES KAREN A
Director
Feb 27 '24
Option Exercise
42.07
4,626
194,616
88,367
DAWES KAREN A
Director
Feb 27 '24
Sale
193.35
1,000
193,350
87,367
Bylund James
Chief Operating Officer
Feb 23 '24
Option Exercise
94.33
940
88,670
18,508
Bylund James
Chief Operating Officer
Feb 23 '24
Sale
198.08
4,373
866,204
14,135
Gebski Christine
See Remarks
Nov 10 '23
Sale
147.13
3,788
557,328
28,787
DAWES KAREN A
Director
Aug 29 '23
Option Exercise
18.12
7,392
133,943
84,591
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company has a collaboration agreement with Navigo Proteins GmbH for the advancement of affinity ligands used in monoclonal antibody (mAb) and non-mAb downstream purification processes. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
medical_instruments_supplies TFX
$211.17
price up icon 0.03%
medical_instruments_supplies COO
$90.20
price down icon 1.61%
$76.71
price down icon 0.62%
medical_instruments_supplies BAX
$40.93
price down icon 0.22%
medical_instruments_supplies RMD
$183.78
price down icon 0.24%
Cap:     |  Volume (24h):